Clinical outcomes in patients with atrial fibrillation with or without concomitant diabetes after two years of edoxaban treatment: ETNA-AF-Europe registry

Abstract Background/Introduction Concomitant diabetes mellitus (DM) in patients with atrial fibrillation (AF) has been associated a higher risk of stroke/systemic embolic events (SEE), and mortality. Purpose To evaluate effectiveness safety outcomes AF different types concomitant DM vs those without after 2 years edoxaban treatment sub-analysis the prospective ETNA-AF-Europe registry. Methods Patients who received once daily were enrolled across 825 centres 10 European countries. This is based on data snapshot from 26th October 2020. grouped by status (with or DM; insulin-treated non-insulin-treated DM). Baseline characteristics are summarised descriptively. Kaplan-Meier (KM) survival curves constructed; annualised event rates (AERs; %/year) comparisons between univariate analysis presented. Comparisons insulin- made multivariate adjusted for HbA1c. Results Patients' demographics baseline shown Table 1. Of 13,133 AF, 2885 (22.0%) had DM. Among DM, 2756 (95.6%) treatment: 605 insulin 2151 (78.0%) non-insulin treatments. KM Figure AERs (%/year) ischaemic stroke/transient attack (TIA)/SEE 0.86% no 0.87% (p=0.9216 DM) 1.81% (p=0.0022 p=0.0014 myocardial infarction (MI) 0.40%, 0.43% (p=0.7454 DM), 1.04% (p=0.0033 respectively; major bleeding 0.90%, 1.10% (p=0.2427 1.71% (p=0.0106 all-cause death 3.36%, 5.02% (p<0.0001 8.91% respectively. In HbA1c (patients measured, n=1869), stroke/TIA/SEE (HbA1c HR [95% CI]: 2.13 [1.12–4.05], p=0.0205) (1.83 [1.35–2.49], p=0.0001) significant difference MI (2.10 [0.78–5.66], p=0.1448) (1.81 [0.95–3.44], p=0.0706) was detected groups. Conclusion stroke/TIA/SEE, confined to only. These also poorer reinforcing previously published showing strong association outcomes, mild/absent treatments Funding Acknowledgement Type funding sources: Private company. Main source(s): research funded Daiichi Sankyo Europe.